Company: BIAF
Filing Date: 2025-05-02
Form Type: S-1
Source: 0001641172-25-008170
Chunk: 5

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-02
Form: S-1
Chunk 5
---
 refund in the event that we do not sell an amount of securities sufficient to pursue our business goals described in this prospectus. In addition, because there is no escrow account, trust or similar arrangement and no minimum offering amount, investors could be in a position where they have invested in our company, but we are unable to fulfill all of our contemplated objectives due to a lack of interest in this offering. Further, any proceeds from the sale of securities offered by us will be available for our immediate use, despite uncertainty about whether we would be able to use such funds to effectively implement our business plan. We will bear all costs associated with the offering. See “Plan of Distribution” for more information regarding these arrangements.

Our Common Stock is listed on the Nasdaq Capital Market under the symbol “BIAF”. Our Tradeable Warrants are listed on the Nasdaq Capital Market under the symbol “BIAFW”. On April 25, 2025, the last reported sale price of (i) our Common Stock on Nasdaq was $0.499 per share, and (ii) our Tradeable Warrants on Nasdaq was $0.227 per Tradeable Warrant. There is no established public trading market for the April 2025 Warrants or the Pre-Funded Warrants, and we do not expect a market to develop. We do not intend to apply for listing of the April 2025 Warrants or the Pre-Funded Warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the April 2025 Warrants and the Pre-Funded Warrants will be limited.

Certain information in this prospectus is based on an assumed public offering price of $0.499 per Share and accompanying April 2025 Warrant (the last reported sale price of our Common Stock on Nasdaq on April 25, 2025). The actual public offering price will be determined between us and the Placement Agent based on market conditions at the time of pricing, and may be at a discount to the current market price of our Common Stock. Therefore, the recent market price per share of Common Stock used throughout this prospectus as an assumed combined public offering price may not be indicative of the final offering price.

We are an “emerging growth company” and a “smaller reporting company” as defined under federal securities laws and, as such, have elected to comply with certain reduced public company reporting requirements for this prospectus and may elect to comply with reduced public company reporting requirements in future